KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Free Cash Flow (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Free Cash Flow for 13 consecutive years, with -$81.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 48.27% to -$81.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$279.9 million, a 51.75% decrease, with the full-year FY2025 number at -$279.9 million, down 51.75% from a year prior.
  • Free Cash Flow was -$81.8 million for Q4 2025 at Xenon Pharmaceuticals, down from -$72.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$14.0 million in Q2 2021 to a low of -$81.8 million in Q4 2025.
  • A 5-year average of -$39.8 million and a median of -$36.0 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: increased 11.71% in 2022, then plummeted 103.04% in 2023.
  • Xenon Pharmaceuticals' Free Cash Flow stood at -$21.2 million in 2021, then tumbled by 74.72% to -$37.1 million in 2022, then grew by 4.32% to -$35.5 million in 2023, then crashed by 55.49% to -$55.2 million in 2024, then tumbled by 48.27% to -$81.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Free Cash Flow are -$81.8 million (Q4 2025), -$72.0 million (Q3 2025), and -$64.4 million (Q2 2025).